Title:
病気に関連するタンパク質のレベルを減少させる方法
Document Type and Number:
Japanese Patent JP2008542200
Kind Code:
A
Abstract:
The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid ² peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, a-synclein, prion protein, tau and superoxide dismutase 1 (SOD1).
More Like This:
| JPWO2005095958 | Assay method for identifying drug candidates |
| JP5039268 | Its use as a benzimidazole and analog and protein kinase inhibitor |
| JP2012021034 | TRANSFECTION SYSTEM |
Inventors:
Samuel Tea, Henderson
Application Number:
JP2008509999A
Publication Date:
November 27, 2008
Filing Date:
March 08, 2006
Export Citation:
Assignee:
Axela Incorporated
International Classes:
A61P21/00; A23L33/00; A61P25/14; A61K45/00; A61P25/16; A61P25/28; A61P43/00; C12Q1/02; G01N33/68
Domestic Patent References:
| JP2001515510A | 2001-09-18 |
Other References:
KASHIWAYA,Y. ET AL: "D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease", PROC NATL ACAD SCI U S A, vol. 97, no. 10, JPN6011048138, 2000, pages 5440 - 4, XP002964865, ISSN: 0002015581, DOI: 10.1073/pnas.97.10.5440
PETTEGREW,J.W. ET AL: "Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode", MOL PSYCHIATRY, vol. 5, no. 6, JPN6011048140, 2000, pages 616 - 32, XP009010394, ISSN: 0002015582, DOI: 10.1038/sj.mp.4000805
KLIVENYI,P. ET AL: "Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis", NAT MED, vol. 5, no. 3, JPN6011048142, 1999, pages 347 - 50, XP008123448, ISSN: 0002015583
PETTEGREW,J.W. ET AL: "Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode", MOL PSYCHIATRY, vol. 5, no. 6, JPN6011048140, 2000, pages 616 - 32, XP009010394, ISSN: 0002015582, DOI: 10.1038/sj.mp.4000805
KLIVENYI,P. ET AL: "Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis", NAT MED, vol. 5, no. 3, JPN6011048142, 1999, pages 347 - 50, XP008123448, ISSN: 0002015583
Attorney, Agent or Firm:
Kazuo Shamoto
Shinjiro Ono
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Ken Matsumoto
Shinjiro Ono
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Ken Matsumoto
Previous Patent: 五塩化リンとＤＭＦからの副生成物としてのオキシ塩化リンの生成及びビ...
Next Patent: １９，２６，２７−トリノル−１α，２５−ジヒドロキシビタミンＤ３化...
Next Patent: １９，２６，２７−トリノル−１α，２５−ジヒドロキシビタミンＤ３化...